New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:00 EDTRHHBY, OSUROraSure raises Q2 EPS view to 1c-2c from (8c)-(9c), consensus (9c)
As a result of the $5.5M payment expected from Roche Diagnostics (RHHBY), OraSure (OSUR) reaffirmed its projected range of consolidated net revenues of $26.0M-$26.5M and is now projecting consolidated net income of approximately 1c-2c per share for Q2, the company stated earlier. The payment from Roche will be recorded as a reduction of the company's operating expenses, OraSure noted. Q2 consensus prior to OraSure's update on Substance Abuse Testing business was (9c) for EPS and $26.2M for revenue.
News For OSUR;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
12:46 EDTRHHBYRoche acquires privately held Dutalys for $133.75M up front
Roche announced that it has agreed to acquire Dutalys GmbH, a privately held biotechnology company based in Vienna, Austria. Dutalys specializes in the discovery and development of fully human, bi-specific antibodies based on their proprietary DutaMab technology, Roche said. Under the terms of the agreement, Roche will make an upfront cash payment of $133.75M to shareholders and make additional contingent payments of up to $355M based on the achievement of certain predetermined milestones.
December 16, 2014
08:47 EDTRHHBYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:46 EDTRHHBYRoche launches PCR molecular diagnostic system for point of care environment
Subscribe for More Information
December 15, 2014
05:24 EDTRHHBYExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 12, 2014
05:52 EDTRHHBYRoche announces retirement of Genentech research head
Subscribe for More Information
December 9, 2014
12:22 EDTRHHBYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
07:44 EDTRHHBYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 5, 2014
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use